Actavis Launches Trimipramine Maleate Capsules In The U.S.

Actavis U.S., the United States manufacturing and marketing division of the international generic pharmaceutical company Actavis Group (ICEX: ACT), announced that it has
received approval from the U.S. Food & Drug Administration to market
Trimipramine Maleate Capsules. Distribution of the product will commence
immediately.



Trimipramine Maleate Capsules, the generic equivalent of Odyssey
Pharmaceutical's Surmontil(R) Capsules, are available in 25mg, 50mg and
100mg strengths. Trimipramine Maleate is indicated for the relief of
symptoms of depression.



Annual brand sales of Trimipramine Maleate capsules in the U.S. were
approximately US$4.2 million for the twelve months ending June 2006
according to IMS Health data.



About Actavis



Celebrating its 50th anniversary this year, Actavis is one of the
world's leading generic pharmaceutical companies specializing in the
development, manufacture and sale of generic pharmaceuticals. Based in
Iceland, the company has operations in over 30 countries, with over 10,000
employees. The company's market cap is approximately EUR2.3bn (US$3
billion) and it's listed in the Iceland Stock Exchange. Actavis expects
2006 sales to total EUR1.4bn, with approximately one-third of these sales
coming from the United States, the company's single largest market. In the
U.S. alone, the company expects to launch 15 new products in 2006, in
addition to filing 30 ANDAs. The company's U.S. operations are located in
New Jersey, Maryland and North Carolina.



More information about Actavis can be found at actavis.



Information in this press release may contain forward-looking
statements with respect to the financial condition, results of operations
and businesses of Actavis. By their nature, forward-looking statements and
forecasts involve risk and uncertainty because they relate to events and
depend on circumstances that will occur in the future. There are a number
of factors that could cause actual results and developments to differ
materially from that expressed or implied by these forward-looking
statements. These factors include, among other things, exchange rate
fluctuations, the risk that research and development will not yield new
products that achieve commercial success, the impact of competition, price
controls and price reductions, the risk of loss or expiration of patents or
trade marks, difficulties of obtaining and maintaining governmental
approvals for products, the risk of substantial product liability claims,
exposure to environmental liability.


Actavis Group

actavis